Showing 7811-7820 of 9909 results for "".
- Dermal Fillers Connected to Body Dysmorphia Disorder?https://practicaldermatology.com/news/dermal-fillers-connected-body-dysmorphia-disorder/2462981/A recent Forbes article suggests a potential connection between dermal fillers and body dysmorphic disorder (BDD), a condit
- GLODERM Announces CeraVe Access Grant Recipientshttps://practicaldermatology.com/news/gloderm-announces-access-grant-recipients/2462970/Five dermatologists working in low-resource settings around the world have been awarded $20,000 each as part of the International Alliance for Global Health Dermatology (GLODERM) Mentorship Programme, which aims to increase access to dermatological care in under-served communities. The new GLODER
- Atopic Dermatitis Not Linked with Increased Risk for Venous Thromboembolismhttps://practicaldermatology.com/news/atopic-dermatitis-not-linked-increased-risk-venous-thromboembolism/2462969/A recent retrospective cohort study published in the latest issue of the Journal of the American Academy of Dermatology showed that venous thromboembolism (VTE) risk among patients with atopic dermatitis (AD) was lower than that of other immune-mediated inflammatory diseases (IMIDs).
- LaserAway Aesthetic Dermatology Chain Welcomes Kelly Lohr as New Customer Officerhttps://practicaldermatology.com/news/laseraway-aesthetic-dermatology-chain-welcomes-kelly-lohr-new-customer-officer/2462909/LaserAway, a prominent aesthetic dermatology chain, has welcomed Kelly Lohr as its inaugural Chief Customer Officer, signaling a move into the health and beauty space, according to a press release from the company. With LaserAway's presence in 145 locations and experiencing significant de
- Lilly Resubmits BLA for Lebrikizumabhttps://practicaldermatology.com/news/lilly-resubmits-bla-lebrikizumab/2462907/Eli Lilly and Company announced as part of its 2024 first-quarter financial report that it as resubmitted the biologic license application (BLA) for lebrikizumab to the U.S. Food and Drug Administration for the treatment of people 12 and older with moderate-to-severe atopic dermatitis (eczema), t
- Review and Analysis: Triple-agent Fixed-dose Combo Tops Acne Treatmentshttps://practicaldermatology.com/news/comparative-effectiveness-moderate-severe-acne-treatments-systematic-review-and-network-meta-analysis/2462740/A topical triple-agent fixed-dose combination (FDC) was shown to be efficacious in comparison to other acne agents, according to result
- Combined Ultrasound and Radiofrequency Promotes Greater Wrinkle Reductionhttps://practicaldermatology.com/news/combined-ultrasound-and-radiofrequency-promotes-greater-wrinkle-reduction/2462721/Using high-intensity focused ultrasound in conjunction with monopolar radiofrequency yielded greater skin tightening and wrinkle reduction than either modality alone, according to new data. High-intensity focused ultrasound (HIFU) and monopolar radiofrequency (RF) are both popular as non-
- Tara L. Azzano Appointed Executive Director of ASDShttps://practicaldermatology.com/news/tara-l-azzano-appointed-executive-director-asds/2462658/The American Society for Dermatologic Surgery (ASDS), the largest organization in the U.S. dedicated solely to dermatologic surgeons, announced the appointment of Tara L. Azzano as Executive Director, according to a news release. Ms. Azzano brings with her over two decades of experience
- Analysis Highlights Factors Affecting Long-term Antibiotic Prescriptions for Acnehttps://practicaldermatology.com/news/analysis-highlights-factors-affecting-long-term-antibiotic-prescriptions-acne/2462633/A new analysis provided insight into the thinking of dermatologists prescribing antibiotics for treating acne. The research team set out to identify factors influencing prolonged oral antibiotic prescriptions for acne treatment by dermatologists, despite guidelines recommending limitation
- ARCA biopharma and Oruka Therapeutics Announce Merger Agreementhttps://practicaldermatology.com/news/arca-biopharma-and-oruka-therapeutics-announce-merger-agreement/2462611/ARCA biopharma and Oruka Therapeutics, a privately held biotechnology company developing novel biologics designed to set a new standard for the treatm